Rebonuputemcel

瑞泊普干赛

Report date: 2026/02/06 20:01:23

Base Information

Drug NameRebonuputemcel

Drug Alias NameInjectable discogenic cell therapyHuman-derived progenitor cell therapyIDCTIDCT-001

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Nucleus pulposus cell therapyCell and gene therapy > Cell therapy > Source of cells > Intervertebral discs-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsIntervertebral Disc Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesJapan

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesDiscgenics Inc

China Registration ClassN/A

Develop Information

Active CompaniesDiscgenics Inc

Inactive CompaniesN/A

Active IndicationsIntervertebral Disc Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A